← Human Trials & Peer-Reviewed Studies
Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder.
Plain-language guide to PMID 2308471 (1990): double-blind controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 boys.
Key Facts
- PMID
- 2308471
- Journal
- Life sciences
- Year
- 1990
- Study type
- Controlled Clinical Trial
- Authors
- Shaywitz BA et al. (7 authors)
- DOI
- 10.1016/0024-3205(90)90131-a
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.
Utilizing a double-blind, drug-placebo design, the researchers examined growth hormone (GH) and prolactin (Pro) response to oral administration of methylphenidate (MPH) in 14 boys (ages 7.0-12.4 years) with Attention Deficit Disorder (ADD).
Behavioral measures included parent ratings on the Yale Children's Inventory and teacher ratings on the Yale and Conners Behavior Rating Scales and Kagan's Matching Familiar Figures Test (MFFT).
Who Took Part
The abstract describes 14 boys taking part.
The age groups tagged for this paper are children, men only.
How the Study Was Run
The design is described as double-blind and placebo-controlled.
Neither the boys nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
GH and Pro response were measured both as maximum peak GH (DGH) or nadir of Pro (DPro) as well as area under the curve for the first four hours after MPH administration (AUCGH, AUCPro).
What Was Measured
Behavioral measures included parent ratings on the Yale Children's Inventory and teacher ratings on the Yale and Conners Behavior Rating Scales and Kagan's Matching Familiar Figures Test (MFFT).
PubMed files the paper under topics including Attention Deficit Disorder with Hyperactivity, Child Behavior, Growth Hormone, Methylphenidate, Prolactin and Psychological Tests.
What This Means in Plain Language
The paper is a double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 boys.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1990 (Life sciences), a journal based in Netherlands.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.